SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-034167
Filing Date
2024-03-20
Accepted
2024-03-20 16:10:48
Documents
84
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K trvi-20231231.htm   iXBRL 10-K 2855240
2 EX-4.2 trvi-ex4_2.htm EX-4.2 31107
3 EX-23.1 trvi-ex23_1.htm EX-23.1 5324
4 EX-31.1 trvi-ex31_1.htm EX-31.1 15343
5 EX-31.2 trvi-ex31_2.htm EX-31.2 15569
6 EX-32.1 trvi-ex32_1.htm EX-32.1 9713
7 EX-32.2 trvi-ex32_2.htm EX-32.2 9403
8 EX-97 trvi-ex97.htm EX-97 23853
9 GRAPHIC img23710298_0.jpg GRAPHIC 34785
10 GRAPHIC img23710298_1.jpg GRAPHIC 43999
  Complete submission text file 0000950170-24-034167.txt   11221568

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20231231.xsd EX-101.SCH 1521004
88 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20231231_htm.xml XML 1864016
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38886 | Film No.: 24767885
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)